Close Menu

More articles about Reimbursement News

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Agendia today said that it has signed a contract with Blue Shield of California, making it an in-network provider.

By Bernadette Toner
Recent comments from a Medicare official indicate the Centers for Medicare & Medicaid Services has no plans to consider reimbursement for whole-genome sequencing-based tests any time soon.

By a GenomeWeb staff reporter


NEW YORK (GenomeWeb News) – Genomic Health today announced it has attained Medicare coverage for its Oncotype Dx colon cancer test.

Molina Healthcare, Paramount Healthcare, and Providence Health Plans join a growing list of health plans that are using McKesson's services to determine the appropriateness of molecular and genetic testing for individual patients.

The insurance industry's trade association has agreed with the Department of Health to not use genetic tests for the majority of policies.

The decision means that "Aetna has decided to pay for AlloMap as a matter of policy," an XDx spokesperson said. Prior to the policy decision, "Aetna would require medical justification for each test to consider whether or not to pay" for it.

The company said that Aetna has determined that AlloMap is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.

The Medco subsidiary signed up a couple of health plans and hospitals to use its personalized medicine services.

The contract will expand coverage for MammaPrint by more than 17 million lives, according to Agendia.

Movers & Shakers: Sep 24, 2010

Premium

Jeffrey Salzman

Starting Aug. 1, Enzo Clinical Lab became part of Empire BCBS's network covering the metropolitan New York City area.

The two-year study will assess the impact of genetic information on determining warfarin dosage and changes in the rate of adverse events when beginning a warfarin treatment regimen.

The firm offers its Avise PG test as a service for physicians making decisions about methotrexate therapy.

The firm claims the test can detect cancers as much as five years earlier than current testing methods.

Pages

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.